Introduction
Early B lymphocyte development is characterized by ordered DNA rearrangements of immunoglobulin (Ig) loci. The stages of development can also be distinguished by the expression of specific cell surface markers. Gene targeting experiments in mice have demonstrated that genes such as Pax-5, 1,2 EBF, 3 E2A, 4 PU.1, 5 Oct-2, 6 Ikaros, 7 RAG-1 8 and RAG-2 9 are required for B cell development. Because B cell development in these mutant mice arrests at an early stage, the precise role of targeted genes is not well understood.
Ikaros, a zinc finger transcription factor, is essential for lymphoid development 7, 10, 11 and for myeloid cell differentiation. 12 The Ikaros gene (Ikaros) encodes, by alternative splicing, at least eight distinct zinc finger isoforms with distinct DNA-binding capabilities, Ikaros isoforms, Ik-1 to Ik-8, the expressions of which are restricted to hematopoietic cells. 10 Three of the Ikaros isoforms, Ik-1, Ik-2 and Ik-3, which contain at least three N-terminal zinc fingers, bind to a sequence of the 4 bp motif GGGA. These DNA-binding isoforms localize in the nucleus. Other isoforms, Ik-4 to Ik-8, which have less than three N-terminal zinc fingers, localize in the cytoplasm and cannot bind to DNA. 10 Mice heterozygous for the Ikaros mutation develop lymphoproliferative disorders and ultimately die of lymphoblastic leukemia or lymphoma, a finding which suggests that non-DNA-binding Ikaros isoforms may be involved in lymphoid malignancies. 11 B-precursor acute lymphoblastic leukemia (pre-B ALL) is characterized by clonal proliferation of transformed pre-B cells. Sun et al 13 reported that infant pre-B ALL cells with t(4;11) chromosome express dominant-negative and mutant isoforms of Ikaros protein and proposed that Ikaros protein is involved in the leukemogenesis of infant pre-B ALL. Nakase et al 14 also showed the expression of dominant-negative Ikaros isoform protein in pre-B ALL. In this study, we also investigated the expression of Ikaros isoforms in 11 leukemia cell lines and primary leukemic cells from 45 adult Japanese patients with pre-B or pre-T ALL. The alteration of the expression of Ikaros isoforms induced by apoptotic stimulation was also examined.
Materials and methods

Leukemic cell lines
Human pre-B cell lines used include RS(4;11), HPB-null, Reh, INC and NALM6 cells. TSB-2, Jurkat, and MOLT-4 cells were human T cell lines used. Human myeloid cell lines, HL60, Kasumi-1 and U937 cells, were also used. All these lines were maintained at a final concentration of 5 ϫ 10 5 cells/ml in RPMI 1640 (Nakarai Chemical, Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Hyclone Laboratories, Logan, UT, USA), 100 U/ml of penicillin-streptomycin, 2 mmol/l L-glutamine, and 5 ϫ 10 Ϫ5 mol/l 2-mercaptoethanol (2-ME) (Sigma Chemical, St Louis, MO, USA). The cells were incubated at 37°C in a humidified atmosphere flushed with 5% CO 2 .
Patients and leukemic cells
Thirty-six Japanese adults with pre-B-ALL and nine with pre-T ALL were investigated after we obtained written informed consent. Leukemic bone marrow (BM) or peripheral blood (PB) samples were collected. Mononuclear cells (MNC) were separated by Ficoll-Hypaque density gradient centrifugation. Samples stored at Ϫ190°C in RPMI 1640 with 20% FCS and 10% dimethylsulfoxide were also used, as needed. In all cases, over 95% of the isolated cells had leukemic cell-like morphology. Immunostaining for leukemic cells was done, as described. 15 Before immunostaining, MNC were treated with 5% heat-inactivated human AB serum to block non-specific binding of antibodies to receptors for IgG Fc portion. CD19 (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), CD20 (Becton Dickinson Immunocytometry Systems), CD22 (Becton Dickinson Immunocytometry System), and CD10 (DAKO, Glostrup, Denmark) were used as B cell markers. CD2, CD3, CD4, CD5, CD7 and CD8, all from Becton Dickinson Immunocytometry Systems, were used as T cell markers. CD11b (Becton Dickinson Immunocytometry Systems), CD13 (CALTAG Laboratories, Burlingame, CA, USA), CD33 (Becton Dickinson Immunocytometry Systems) and CD34 (Becton Dickinson Immunocytometry Systems) were used as myeloid or stem cell markers. For cytoplasmicIgM (cIgM) staining, the cells were suspended in staining buffer containing 0.05% saponin (Sigma Chemical) and 10 mmol/l N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (Hepes), pH 7.3, and stained as for the cell surface staining using anti-human IgM (DAKO). Throughout staining and washing procedures, 0.05% of saponin was kept in buffer. The stained cells were applied to flow cytometric analysis with FACScan (Becton Dickinson Immunocytometry Systems). Cells present in the blast cell gate defined by light scatter were analyzed. Patients with over 50% of blasts expressing CD19, CD22, and HLA-DR (Becton Dickinson Immunocytometry Systems) and lacking surface immunoglobulins were diagnosed as pre-B ALL. Pre-T ALL was diagnosed when over 30% of the leukemic cells was positive for CD7 and cytoplasmic CD3, over 70% was negative for CD19, and the cells lacked myeloperoxidase (MPO) activity. Thirty-eight adult pre-B ALL samples were also categorized into three immunophenotypically defined subgroups: [15] [16] [17] [18] 19 
Expression of Ikaros in cell lines or primary leukemic cells by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
RNA was extracted from cell lines or primary leukemic cells and the expression of Ikaros was studied using RT-PCR, as described. 17 PCR was performed for 28 cycles, under the following conditions: 1.5 min at 95°C for denaturating, 2 min at 60°C for annealing, and 2 min at 72°C for extending. The oligonucleotide primers were used as follows: Ikaros sense, 5Ј-CCC CCT GTA AGC GAT ACT CCA GAT-3Ј; Ikaros antisense, 5Ј-GGC TTG GTC CAT CAC GTG GGG A-3Ј; ␤-actin sense, 5Ј-GTG GGG CGC CCC AGG CAC CA-3Ј; ␤-actin anti-sense, 5Ј-GTC CTT AAT GTC ACG CAC GAT TTC-3Ј. 20 The PCR products were electrophoresed in a 3% agarose gel, in comparison to the molecular-weight ladder (174 digested by HaeIII) and stained with ethidium bromide for viewing under UV illumination.
Cloning and sequencing of PCR products
The sequencing analysis of RT-PCR products was performed as previously described. 21 Briefly, the PCR products were purified by electrophoresis and recovered from the gel, using QIAquick Gel Extraction kits (Qiagen, Chatsworth, CA, USA). The recovered DNA was ligated into the pCR2.1 vector (TA cloning kit; Invitrogen, San Diego, CA, USA). Using the method of blue-white selection with X-Gal (TaKaRa Biochem, Kyoto, Japan), five to 10 white colonies were picked up at random and grown overnight in 2.5 ml of Luria-Bertani (LB) medium. Minipreps of plasmid were prepared from cultures by alkaline lysis and purification of DNA affinity columns (QIAprep Spin Plasmid kit; Qiagen), according to the manufacturer's protocol. The double-stranded plasmid was sequenced in an automatic DNA sequencer (Applied Biosystems 373; Applied Biosystems, Foster City, CA, USA), using the dye terminator cycle sequencing method. For each patient, the procedures of PCR and sequencing were performed independently at least twice.
DNA-binding assay
Proteins were extracted from leukemic cell lines or primary leukemic cells and electrophoretic mobility shift assay (EMSA) was carried out, as described. 22 The following 32 P-labeled probes containing Ikaros protein binding sequence were used: sense, 5Ј-GTT TCT TCA GAG CCT GGG AAA CAA GTC-3Ј; anti-sense, 5Ј-ATT CTG ACT TGT TTC CCA GGC TCG AA-3Ј. The DNA-protein binding interaction was carried out in 20 l of 10 mM Tris-Cl, pH 8.0 containing 5 mM MgCl 2 , 100 mM KCl, 1 mM CaCl 2 , 2 g poly dI:dC, 20 000 c.p.m. DNA, and 5 g nuclear protein or cytoplasmic protein extracts. The mixture was incubated at 25°C for 15 min, reacted with 0.25% bromophenol blue and 39% glycerol, and applied to a 6% native polyacrylamide gel (19:1). Electrophoresis was done at 50 V for 6 h in Tris-glycine buffer and the gel was dried and autoradiographed. After a 100-fold molar excess of the competing non-labeled oligonucleotide had been added to the mixture containing the labeled oligonucleotide, the gel shift competition experiments were done. For supershift experiments, 1 g of polyclonal antibody against Ikaros protein was added to the binding reaction mixture 20 min prior to the addition of the 32 P-labeled wild-type probe. Anti-Ikaros polyclonal antibody was kindly provided by Dr Katia Georgopoulos (Harvard Medical School, Boston, MA, USA).
Subcellular localization studies using confocal laser scanning microscopy
The subcellular localization of Ikaros protein was examined by immunofluorescence and confocal laser scanning microscopy, as described previously. 23 Cells were attached to glass cover slips by a 30-min incubation at room temperature, were washed twice with Ca 2+ , Mg2 + -free phosphate-buffered saline (PBS), and then fixed in methanol for 15 min. To permeabilize the cells and block the nonspecific antibody binding sites, cells were treated with 10% goat serum in PBS for 30 min. To detect Ikaros protein, the cells were incubated with an affinity-purified polyclonal rabbit anti-Ikaros antibody of 1:200 dilution for 2 h at room temperature. Cells were washed with PBS and then incubated with an Alexa 488 goat anti-rabbit IgG (H+L) conjugate highly cross-adsorbed (Molecular Probes, Eugene, OR, USA) at a 1:40 final dilution for 1 h. Finally, nuclei were stained with 0.5 g/ml propidium iodide (PI) (Sigma Chemical).
Cell culture and irradiation
Leukemic cell lines and primary leukemic cells were cultured in a 25 cm 2 flask at a final concentration of 5 ϫ 10 5 cells/ml. Five hundred thousand cells were treated with 300 rad of radiation and then cultured without FCS. RNA was extracted from the cells before and after several hours of re-culture, then, expression of Ikaros isoforms in each sample was examined.
Results
Expression of Ikaros and sequencing PCR products in leukemic cell lines
We first investigated the expression of Ikaros in several leukemic cell lines, using RT-PCR analysis. As shown in Figure  1 and Table 1 10 we next determined if these RT-PCR products from leukemic cell lines were the isoforms of Ikaros. Sequencing analysis revealed that the long product of Ikaros from NALM6 cells was Ik-1, while the shortest product of Ikaros from INC cells was a non-DNAbinding isoform of Ikaros, Ik-6. Mutation or deletion sequence of Ik-6 from INC cells was nil (data not shown). We also confirmed that other RT-PCR products were Ik-2/3 and Ik-4. In our RT-PCR products from leukemic cell lines, Ikaros isoforms of Ik-5, Ik-7 and Ik-8 were not detected.
Figure 1
Ikaros isoforms are expressed in leukemic cell lines. Expression of Ikaros isoforms was examined in leukemic cell lines, using RT-PCR analysis. PCR products were detected by ethidium bromide staining of 3% agarose gels after 28 cycles of amplification. Sequence analysis of the PCR products indicated that the smallest and largest products were Ik-6 and Ik-1, respectively. 
Expression of Ikaros gene was examined, using RT-PCR analysis. +, expressed; Ϯ, weakly expressed; Ϫ, not expressed.
DNA-binding of Ikaros protein in INC and NALM6 cells
DNA-binding capacity of the protein extracts from INC and NALM6 cells was tested, using EMSA ( Figure 2a ). We used the probe which contained the Ikaros protein binding site.
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When protein extracts were incubated with the radiolabeled oligonucleotide probe, protein-DNA complex bands were evident in the extracts from NALM6 cells (arrow). In contrast, in the extracts from INC cells only one very weak protein-DNA complex band was found. We cannot confirm whether a small amount of DNA-binding Ikaros protein exists in INC cells or this weak band is caused by nonspecific binding. Binding specificity of the oligonucleotide probe was also examined using a 100-fold molar excess unlabeled oligonucleotide probe. To determine if Ikaros protein was present in the complexes, supershift EMSA analysis was performed using the anti-Ikaros antibody. Upon addition of the anti-Ikaros antibody, specific protein-DNA complexes (Figure 2b , arrow 1) were reduced and the shifted band (arrow 2) was considerably detected in the protein extracts from NALM6. These results suggest that DNA-binding Ikaros proteins are expressed in NALM6 cells but not in INC cells.
Subcellular localization of Ikaros protein in leukemic cells
We examined the subcellular compartmentalization of Ikaros protein in pre-B ALL cell lines, NALM6 and INC cells, using confocal laser scanning microscopy ( Figure 3 ). Cells were stained with Ikaros antibody (FITC, green) and nuclei were stained with PI (red). In NALM6 cells which expressed Ik-1 and Ik-2/3 but not Ik-6, Ikaros protein was stained in the nuclei. In contrast, the expression of Ikaros protein was detected in only the cytoplasm of INC cells which expressed Ik-6 alone. These observations are consistent with previous reports showing nuclear and cytoplasmic localizations of Ik-1 and Ik-6 proteins, respectively.
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Expression of Ikaros isoforms in primary leukemic cells
We next examined the expression of Ikaros in adult primary acute leukemic cells, including pre-B ALL and pre-T ALL cells, 
Figure 3
Ikaros protein expression was located in the cytoplasm of the cells expressing Ik-6 alone. Localization of Ikaros protein in NALM6 and INC cells was analyzed, using confocal laser scanning microscopy. The cells were stained with a rabbit polyclonal antibody against Ikaros protein, followed by a FITC-conjugated anti-rabbit goat antibody (green). The nuclei of these cells were also stained using Pl (red). NALM6 cells showed the expression of Ikaros protein only in the nuclei (seen as yellow).
using RT-PCR analysis. All tested pre-B ALL cells expressed several isoforms of Ikaros. Predominant expression of Ik-6 was detected in 16 of 36 of pre-B ALL samples. Interestingly, functional Ikaros isoforms, Ik-1 and Ik-2/Ik-3, were not detected in Ik-6-expressing cells ( Figure 4 and Table 2 ). Several isoforms of Ikaros were also expressed in nine pre-T ALL samples under our PCR condition, however, the expression of Ik-6 was nil ( Figure 5 and Table 3 ). These results suggest that a non-DNAbinding Ikaros isoform, Ik-6, was expressed in pre-B ALL but not pre-T ALL in adults. It should be noted that Ik-6 was frequently expressed in stages II and III pre-B ALL, whereas Ik-6 was not detected in CD19 + CD10 Ϫ stage I pre-B ALL cells. Among stage III pre-B ALL, all cIgM + pre-B ALL cells expressed Ik-6 ( Table 4 ). The association of Ik-6 expression with karyotype abnormalities such as t(9;22) or t(4;11) was not observed (Table 2) . To determine if chemotherapy would alter Table 2. the expression of Ikaros isoforms, we studied the expression manner of Ikaros isoforms in leukemic cells obtained from four pre-B ALL patients, cases BL11, BL12, BL17 and BL19, prior to chemotherapy and after relapse. The expression manner of Ikaros isoforms in cases of relapse was the same as that seen prior to chemotherapy (Table 2) . 
,XY,t(5;9;22),t(7;12),del(9)(p22)
Phenotypical analysis of pre-B ALL was done, using flow cytometry. Expression of Ikaros isoforms in each sample was examined, using RT-PCR analysis. BL11R, BL12R, BL17R and BL19R were cases in relapse. BL, pre-B ALL; NT, not tested; +, expressed; Ϯ, weakly expressed; Ϫ, not expressed.
Expression of Ikaros in normal human BM pre-B cells
Klug et al 12 reported that murine BM progenitor cells expressed Ik-6, and also Payne et al 26 showed that a small population of the Ik-6-expressing cells may exist in normal human BM. To determine if a population of normal human pre-B cells expresses Ik-6, CD19 
CD10
Ϫ pre-B cells in our 28 cycle RT-PCR analysis. These findings suggest that the expression of Ik-6 detected in primary pre-B ALL cells is not due to contamination of normal BM pre-B cells.
Leukemia
Alteration of Ikaros isoform expression by apoptotic stimulation
As it has been reported that Ikaros isoforms are produced by alternative splicing, it is possible that the expression of these isoforms may change in response to environmental factors such as apoptosis-inducing stimulation. Exposure to X-rays and withdrawal of FCS are well known to induce apoptosis on leukemic cells, 27 ,28 therefore, we next studied the effects of these stimulations on the expression of Ikaros isoforms in NALM6 and INC cells (Figure 7) . We re-cultured NALM6 and INC cells in the absence of FCS following their exposure to X-rays. RNA was extracted from the cells before and after 4, 6 and 24 h of re-culture and the expression of Ikaros isoforms (6) 
Phenotypical analysis of pre-T ALL cells was done, using flow cytometry. Expression of Ikaros isoforms in each sample was examined using RT-PCR analysis. TL, pre-T ALL; NT, not tested; +, expressed; Ϯ, weakly expressed; Ϫ, not expressed.
Discussion
Mice homozygous for the mutation of Ikaros lack lymphocytes, NK cells and their progenitors because of a complete block in early lymphocyte development. 29 Sun et al 13 
CD10
Ϫ CD20 Ϫ phenotype. 13 Nakayama et al 30 showed that a non-DNA-binding Ikaros isoform, Ik-6, is expressed in the cells of lymphoid crisis in chronic myelogenous leukemia. In our adult pre-B ALL cases, no relationship between the expression of Ik-6 and karyotypes such as t(4;11) or t(9;22) was found. Indeed, adult pre-B ALL cells of cases BL1 and BL3 with the t(4;11) karyotype did not express Ik- 6 . Surprisingly, the expression of Ik-6 was detected in CD19 +
+ but not in CD19 + CD10 Ϫ pre-B ALL cells, suggesting that the expression of Ik-6 in pre-B ALL may be restricted to CD10
+ pre-B ALL cells in adults. These findings imply that the characteristics of pre-B ALL, including leukemogenesis, differ between adult and infant patients. It was reported that infant pre-B ALL may originate from an in utero initiating event. 31, 32 Exploration of the origin of adult pre-B ALL will aid in understanding the differences between adult and infant pre-B ALL. Our finding that expression of Ik-6 was frequently detected in cIgM + pre-B ALL cells but not in normal BM pre-B cells suggests that the expression of non-DNA-binding Ikaros, Ik-6, may play an important role in the characteristics of adults pre-B ALL. Further studies are necessary to address this issue.
Mice heterozygous for the mutation of the Ikaros develop 
+ and CD19
+
CD10
Ϫ cells was examined by RT-PCR analysis. We also used ␤-actin primers as a control. The bands were detected by ethidium bromide staining. The left lane is the molecular size marker, 174 digested by HaeIII.
T cell leukemia and/or lymphoma.
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In humans, the expression of Ik-6 and/or an inframe deletion of Ikaros was detected in childhood pre-T ALL. 23 In the present study, the expression of Ik-6 was not detected in adult pre-T ALL samples and mutation or deletion in Ik-1 in these samples was nil. This discrepancy may also result from differences between adult and childhood pre-T ALL. It can be speculated that the abnormal expression of Ikaros isoforms may occur in B cell precursors but not in T cell precursors in adults.
We observed that INC and primary pre-B ALL cells which express Ik-6 alone led to the production of Ik-1 in response to apoptotic stimulation, including irradiation and starvation. Moreover, when the cells were re-exposed to FCS, the level of Ik-1 decreased. These results suggest that Ik-6-expressing cells have the potential to produce other Ikaros isoforms in response to their environmental alteration. Signals which are antagonized by apoptotic stimulation induced by irradiation and starvation may give rise to the predominant expression of Ik-6 in adult pre-B ALL. Further studies on the mechanism(s) of predominant expression of Ik-6 are expected to determine the clinical relevance of post-transcriptional dysregulation of Ikaros isoforms in adult pre-B ALL.
Leukemia
Figure 7
Expression of Ikaros isoforms is modulated by apoptosisinducing stimulation. Effects of FCS withdrawal following exposure to X-rays on the expression of Ikaros isofroms were examined in NALM6, INC and primary pre-B ALL cells from cases BL12, BL19, BL31 and BL35, using RT-PCR analysis. We used Ikaros primers and ␤-actin primers. The bands were detected by ethidium bromide staining. Lane 1, before; lane 2, 4 h, lane 3, 6 h, lane 4, 24 h after FCS withdrawal following exposure to X-rays; lane 5, FCS was added again to the culture medium 24 h after exposure to X-rays, then, RNA was isolated 48 h later. The results are representative of three independent experiments.
